F-14258 is a serotonin 5-HT1B and 5-HT1D receptor antagonist which was under development for the treatment of major depressive disorder (MDD) and obsessive–compulsive disorder (OCD) but was never marketed. It is taken orally. The drug was under development by Pierre Fabre. It reached the preclinical research stage of development prior to its discontinuation around 2002.
See also List of investigational antidepressants List of investigational obsessive–compulsive disorder drugs F-12682
References